Cargando…

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study

BACKGROUND: Upfront resection (UR) followed by adjuvant chemotherapy remains the standard treatment for resectable pancreatic cancer. There is increasing evidence suggesting favourable outcomes toward neoadjuvant chemotherapy (NAC) followed by surgery. METHODS: All clinical staging with resectable p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yung-Yeh, Chao, Ying-Jui, Wang, Chih-Jung, Liao, Ting-Kai, Su, Ping-Jui, Huang, Chien-Jui, Chiang, Nai-Jung, Yu, Yu-Ting, Tsai, Hong-Ming, Chen, Li-Tzong, Shan, Yan-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498854/ https://www.ncbi.nlm.nih.gov/pubmed/37300888 http://dx.doi.org/10.1097/JS9.0000000000000495

Ejemplares similares

The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Author Correction: The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
por: Su, Yung-Yeh, et al.
Publicado: (2020)

Percutaneous Computed Tomography-Guided Coaxial Core Biopsy for the Diagnosis of Pancreatic Tumors
por: Su, Yung-Yeh, et al.
Publicado: (2019)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study
por: Huang, Chien-Jui, et al.
Publicado: (2022)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer
por: Hou, Ya-Chin, et al.
Publicado: (2022)

Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2022)

No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
por: Shan, Yan-Shen, et al.
Publicado: (2021)

A commentary on ‘The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study’
por: Chen, Yuan, et al.
Publicado: (2023)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan
por: Shan, Yan-Shen, et al.
Publicado: (2020)

Impact of body mass index on the early experience of robotic pancreaticoduodenectomy
por: Chao, Ying-Jui, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy
por: Chao, Ying-Jui, et al.
Publicado: (2014)

Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications
por: Deig, Christopher Ryan, et al.
Publicado: (2022)

Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
por: Yen, Chih-Chieh, et al.
Publicado: (2021)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
por: Ren, Xiaohan, et al.
Publicado: (2019)

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Jung, Hye-Sol, et al.
Publicado: (2022)

Diabetes Upregulates Oxidative Stress and Downregulates Cardiac Protection to Exacerbate Myocardial Ischemia/Reperfusion Injury in Rats
por: Chien, Chen-Yen, et al.
Publicado: (2020)

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
por: Shrestha, Bikram, et al.
Publicado: (2017)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity
por: Hill, Colin S., et al.
Publicado: (2022)

The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
por: Zwart, Eline S., et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Feasibility of simultaneous development of laparoscopic and robotic pancreaticoduodenectomy
por: Chao, Ying-Jui, et al.
Publicado: (2023)

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Zou, Yiping, et al.
Publicado: (2023)

The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases
por: Altman, Ariella M., et al.
Publicado: (2022)

Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
por: Chiu, Tai-Jan, et al.
Publicado: (2021)

Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer
por: Huang, Chun-Ming, et al.
Publicado: (2017)

Effectiveness of Acupuncture in Relieving Chemotherapy-induced Leukopenia in Patients With Breast Cancer: A Systematic Review With A Meta-Analysis and Trial Sequential Analysis
por: Shih, Ya Wen, et al.
Publicado: (2021)

Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
por: Chen, Chia-Yu, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic cancers
por: Inoue, Yosuke, et al.
Publicado: (2022)

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis
por: Lee, Yoon Suk, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_opvpfequ2tk2ergpkcmqcl1noj